New Aristos success in the SME Instrument Phase 1, November 2018

///New Aristos success in the SME Instrument Phase 1, November 2018

Great success of Aristos in the November 2018 call of the SME Instrument Phase 1!

In the November 2018 call of the SME Instrument phase 1, three Aristos clients have been winners and have received the funding they needed to carry out their projects. For us it is great news and we want to congratulate our clients for this success!

Below, we present the names and a brief description of these great projects:

1.Tol2 by Toleranzia: An innovative therapy with potential to cure Myasthenia Gravis (MG), a disease of the neuromuscular junction that affects 2 out of every 10,000 people.

2. Haiku by Remab Therapeutics : A new pharmacological product and a first line therapy to prevent and cure infectious diseases in ICUs based on the elimination of inhibitory antibodies, which are used by bacteria to facilitate their infectivity.

3. CKDSens by Creatsens: a new platform for the personalized management of renal function, which decentralizes the analysis of biomarkers with new diagnostic systems, that is, it takes them from the hospital to the patient’s home. Thanks to this, health professionals will waste less time and money in the analyzes.

From Aristos we are very pleased to have helped them to achieve their success and we wish them good luck in this first phase of their projects!

Follow us on Twitter.

2019-02-15T12:43:17+00:00January 16th, 2019|Categories: News, Success Cases|0 Comments

Leave A Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.